Bio


Khalid Salaheldin, MD serves as Clinical Assistant Professor and interventional psychiatrist in the Department of Psychiatry & Behavioral Sciences at Stanford University School of Medicine. Dr. Salaheldin specializes in the management of individuals presenting with first episode psychosis and early psychosis.

His current work at Stanford spans evaluating patients in the early psychosis INSPIRE clinic, inpatient psychiatric unit, and the interventional psychiatry services; alongside teaching, research, and continuing to learn from his patients & colleagues.

His treatment philosophy is a holistic and compassionate approach evaluating vital underlying factors alongside pharmacotherapy & neuromodulatory interventions including: sleep, exercise, nutrition, mindfulness, therapy integration, underlying medical issues, substance use, psychosocial history, and importantly patients’ current relationships (including pets of course!). His approach focuses on meeting patients where they are at in their health journey, aligning treatment with their personal goals, and being actively present in their management.

Dr. Salaheldin’s research interests include early psychosis interventions, underlying medical causes of psychiatric symptoms, neuromodulation, community/global mental health, spirituality and mental health, healthcare worker mental health, novel psychiatric therapeutics, and mental health parity & policy.

Prior coming to Stanford, Dr. Salaheldin’s work as academic chief resident at Northwell Health focused on piloting a consult liaison service for first episode psychosis that compassionately assists patients and their families from once they enter the emergency room, through their inpatient admission and into the outpatient setting.

We kindly request that patients do their best to provide the clinic with their previous blood work, imaging reports and medical history paperwork prior to the appointment in order to have the most complete initial evaluation.

“True compassion means not only feeling another's pain, but also being moved to help relieve it. ” —Daniel Goleman

Clinical Focus


  • Psychiatry
  • Early Psychosis Interventions
  • Schizophrenia
  • Interventional Psychiatry
  • Novel Therapeutics
  • Preventative Psychiatry/Medicine

Academic Appointments


  • Clinical Assistant Professor, Psychiatry and Behavioral Sciences

Administrative Appointments


  • Assistant Medical Director, INSPIRE Clinic (2022 - Present)

Honors & Awards


  • Academic Chief Resident, Northwell Health (2020-2021)
  • Biology Scholars Program, UC Berkeley (2008-2009)

Professional Education


  • Medical Education: St George's University School of Medicine Grenada West Indies (2017) NY West Indies
  • Board Certification: American Board of Psychiatry and Neurology, Psychiatry (2021)
  • ABPN Dipolmate, Board Certification, American Board of Psychiatry and Neurology, Psychiatry (2021)
  • Residency: Zucker School of Medicine at Hofstra Northwell GME Program (2021) NY
  • BA, University of California Berkeley, Public Health (2009)
  • BA, University of California Santa Cruz (Transfer to UC Berkeley) (2007)
  • HSDG, Lowell High School, San Francisco, CA (2005)

Clinical Trials


  • A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms Recruiting

    This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.

    View full details

  • Improving Cognition Via Exercise in Schizophrenia Recruiting

    People with schizophrenia display a broad range of cognitive impairments that have been identified as major determinants of poor functioning and disability. Also, people with schizophrenia are at increased risk for suicide, with approximately 40-50% of individuals attempting to take their own lives during their lifetime. The goal of the proposed study is to examine the impact of remote exercise training on cognition, suicide risk, daily functioning, and biomarkers of cognitive change and suicidality in people with schizophrenia.

    View full details

  • Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 Recruiting

    This study will evaluate the long-term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder

    View full details

Projects


  • The Genomics of Electroconvulsive Therapy (ECT)

    IRB-54241

    Location

    stanford, ca

All Publications


  • I THINK MY PATIENT MAY BE EXPERIENCING PSYCHOSIS - NOW WHAT? HOW PROVIDERS CAN SUPPORT EARLY IDENTIFICATION AND INTERVENTION. Eisen, K., Chari, S., Salaheldin, K., Zepp, C., Ballon, J., Hardy, K. OXFORD UNIV PRESS INC. 2022: S1
  • The relationship between prototype ratings of personality and self and interpersonal functioning with an adolescent inpatient sample CLINICAL PSYCHOLOGY & PSYCHOTHERAPY Haggerty, G., Esang, M., Salaheldin, K., Lima, A. 2021; 28 (2): 364-372

    Abstract

    Personality pathology is conceptualized, in part, as impairments in self and interpersonal functioning. Although most of the research has focused on adult samples, fewer have looked at this relationship in adolescent samples. This paper investigates the relationship between clinician-rated personality prototypes, the Shedler-Westen Assessment Procedure-Prototype Matching Adolescent Version (SWAP-A-P) derived from the SWAP-II-A, and a measure of self and interpersonal functioning, the Social Cognition and Object Relation Scale-Global Rating (SCORS-G). Clinicians rated 66 adolescents hospitalized at a safety net teaching hospital in the northeast. The patient's individual and group therapist rated the patients at discharge using the SWAP-A-P and the SCORS-G at discharge blind to each other's ratings. Results showed that more severe personality pathology was linked with more impairments in self and interpersonal functioning.

    View details for DOI 10.1002/cpp.2512

    View details for Web of Science ID 000585999700001

    View details for PubMedID 32881158

  • Phobias 5MinuteConsult Farooq, U., Salaheldin, K. Wolters Kluwer. 2020